Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million) Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million) Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMA Chinese (Mandarin) investor event with simultaneous conference call and webcast at 10:00 am HKT on March 26, 2026 / 10:00 pm EDT on March 25, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on March 26, 2026ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred hereinto as “Ascentage...

BROSSARD, Quebec, March 25, 2026 (GLOBE NEWSWIRE) — G Mining Ventures Corp. (“GMIN” or the “Corporation”) (TSX:GMIN, OTCQX:GMINF) today reported its financial and operating results for the fourth quarter and full year ended December 31, 2025. Unless otherwise indicated, all dollar amounts are in U.S. dollars. “Tocantinzinho completed its first full year of commercial production in 2025, delivering consistent operating performance with production, recoveries and costs in line with expectations,” said Louis-Pierre Gignac, President and Chief Executive Officer. Production, costs and recoveries largely met or exceeded guidance, underscoring the asset’s reliability and operational discipline. The operation generated $255 million in free cash flow, strengthening our balance sheet while funding the advancement of Oko West. Fourth quarter...

Press release26 March, 2026 Fiscal-year 2025 results: AFL Group delivers record results, doubling its net profit Dynamic activity and record results in 2025      Key figures as at 31/12/2025 (IFRS)  AFL Group1 (consolidated – IFRS)  AFL2 (consolidated – IFRS)  Net banking income  €30.8m (+28% Year-on-Year – YoY) €30.7m (+29% YoY)Operating expenses €17.5m (+8% YoY)   €17.5m (+9% YoY)Gross operating income   €13.3m (+69% YoY) €13.3m (+70% YoY)Net income before tax  €13.3m (+78% YoY) €13.3m (+79% YoY)Net profit   €10.8m (+100% YoY) €10.8m (+100% YoY)Cost income ratio3   64.4% (vs. 67.8% on 31/12/2024) 64.3% (vs. 67.7% on 31/12/2024)Record fiscal-year resultsNet banking income strongly grew broadly in line with the increase in outstanding loans, which exceeded €10 B as at 31 December, 2025. Gross...

Amsterdam, March 25, 2026 Press Release 2025 ANNUAL REPORT: UNIBAIL-RODAMCO-WESTFIELD N.V. (EURONEXT: URW) Unibail-Rodamco-Westfield N.V. (“URW NV” or the “Company”) today released its 2025 Annual Report. The Company’s 2025 Annual Report, including the Management Board Report and the audited Financial Statements for the fiscal year ended December 31, 2025, can be found on URW N.V. website (section Investors). URW NV’s portfolio consists of assets in the United States and The Netherlands. URW NV and its consolidated entities, together with Unibail-Rodamco-Westfield SE (“URW SE”) and its consolidated entities, form Unibail-Rodamco-Westfield Group (“URW”). URW SE consolidates URW NV and its controlled undertakings. The 2025 Universal Registration Document of URW SE, including the accounts, provides a comprehensive overview of URW and is available...

VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) — Liberty Gold Corp. (TSX:LGD; OTCQX:LGDTF) (“Liberty Gold” or the “Company”), is pleased to announce its financial and operating results for the fiscal year ended December 31, 2025. All amounts are presented in United States dollars unless otherwise stated. RECENT PROJECT HIGHLIGHTS – BLACK PINE During 2025 and early 2026, Liberty Gold advanced the Black Pine Gold Project (“Black Pine” or the “Project”) through resource growth, commencement of a feasibility study, and key federal permitting milestones, while also executing strategic corporate initiatives. At the Black Pine project in IdahoOn March 23, 20261, we announced that a coordinated federal and state permitting schedule has been posted to the United States government permitting dashboard, pursuant...

Strong performance across Pilgrim’s Pride, JBS Australia and Seara showcases breadth of the JBS portfolio; earnings per share of US$ 1.89 reflect 15% growth GREELEY, Colo., March 25, 2026 (GLOBE NEWSWIRE) — JBS today announced financial results for the fourth quarter and full year ended December 31, 2025, which included record net revenue of US$ 86 billion, an increase of 12% compared to 2024. Net income for the full year 2025 grew 13%, reaching US$ 2 billion. The strong performance was driven primarily by Pilgrim’s Pride Corporation, JBS Australia and Seara, all of which delivered significant organic growth and value creation. The results underscore the resilience of the company’s global multiprotein and multiplatform strategy across diverse market environments. JBS reported adjusted EBITDA under IFRS of US$ 6.8 billion, with an...

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) — “This year, we delivered solid net earnings driven by significant investment gains across our mining portfolio, alongside sizeable monetization transactions that strengthened Dundee’s year-end cash position and financial flexibility,” said Jonathan Goodman, President and Chief Executive Officer of Dundee Corporation. “With a strong balance sheet and ample liquidity, we are in a strong position to redeploy capital toward returns-focused growth and deliver sustained shareholder value.” “Our recently announced earn-in and joint-venture agreement with Westhaven Gold is a clear example of our disciplined approach to deploying capital to build a scalable, long-term mining platform,” Mr. Goodman continued. “The agreement provides Dundee with a path to earn a meaningful interest in Westhaven’s...

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales Expanded strategic collaboration with Fermbox Bio, including the launch of animal-origin-free recombinant DNase I (RNase-free) as the first commercialized product under the expanded partnership Signed an OEM distribution agreement with IBT Bioservices to commercialize Dyadic’s recombinant DNase I and transferrin for research and cell culture applications through IBT’s global distribution channels Entered a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin for global nutrition markets, which includes funded development, milestones, and potential revenue participation Inzymes...

  ● Q4 2025 Revenue of $25.2 million  ● Q4 2025 Net loss of $4.6 million  ● Q4 2025 Adjusted EBITDA loss of $0.3 million     All results are reported in United States dollars ($) unless otherwise indicated. LAS VEGAS, March 25, 2026 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated cannabis company, today announced its financial results for the three-month and twelve-month periods ended December 31, 2025. Planet 13’s financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). “Q4 began the turnaround we were looking for. Revenue stabilized across our footprint during a seasonally soft period, wholesale momentum returned in Nevada, and we exited the quarter with a cleaner, more focused...

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025. 2025 Financial Results Cash Position: Cash and cash equivalents were $3.7 million as of December 31, 2025, compared to $12.5 million as of December 31, 2024. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be required to support ongoing operations, continue the exploration of strategic alternatives, and pursue any alternatives that we identify. Research and Development (R&D) Expense: Research and development expenses were $3.3 million for the year ended December 31, 2025, as compared to $0 for the year ended December 31, 2024. The increase of $3.3 million reflects R&D activities...